Small molecule inhibition of BRD4 (such as JQ1 and BET inhibitors) has been shown to reduce cell proliferation and survival in vivo as well as increase therapeutic sensitivity of several cancer types, leading to the development of several clinical trials20,23,24. This evidence concerns the gene BRD4 and cancer.